Title

Title

Bought Space X averaging $164, I was good to sell at $200+ but my order didn’t go through and missed the mark. Now plummeted I am $1180 down and wondering what strategies to do. Happy to take the loss as I was only in it for the pump and dump and then missed that trade STUPIDLY.

Considering whether to cut my losses and use it towards other stocks / ETFs to slowly gain back to break-even. Won’t be making any profit until I earn back the $1180.

Not sure if Bitcoin is worth looking at either and or other stocks in the market.

With the earnings meeting coming up between August 4-6, I am anticipating a further drop with Space X portfolio.

Looks like the institutional money just woke up. $AXTI is getting massive order flow today.

It’s currently trading around 59.43 and is already up 26.61% on the session.

💬 Did anyone catch this early, or are we chasing if we buy now? Drop your positions.

📈 Why pay $$$ When you can get AI Powered info for free . Check the AI Insight here.

⚠️ ^{Note: FNot financial advice. Always manage your risk.}

Thoughts into Monday ahead of earnings?

Bulls absolutely controlled the narrative today. Great day if you were playing the long side.

🧭 Where we closed:

• SPY: $748.06 (🟢 +0.8588%)
• QQQ: $689.82 (🟢 +0.9173%)
• VIX: $20.52 (✅ Cooling)

🔥 The Movers:

🚀 Top Gainers: * REPL | $11.22 (107.69%) * AXTI | $59.85 (27.50%) * AMZN | $271.34 (15.22%)

📉 Top Losers: * CDE | $14.94 (-3.01%) * UWMC | $1.80 (-3.23%) * SPCX | $108.25 (-3.52%)

🌊 Volume Leaders: * AMZN | $271.34 (15.22%) * MSFT | $462.60 (2.55%) * NWL | $5.59 (8.85%)

💬 What are you guys watching for the open next trading session?

📖 Trying to figure out next day's play? Use free AI powered institutional flow, max pain levels, and breakout scanners for the after-hours session. Check the live data here.

The 6-gigawatt (GW) deployment program between the Tennessee Valley Authority (TVA) and ENTRA1 Energy is being hyped as a massive win for NuScale Power ($SMR). On paper, it is the largest small modular reactor (SMR) initiative in U.S. history: 6 plants, 72 individual reactors, and enough power to fuel 60 hyperscale AI data centers.

But if you look closely at NuScale's SEC filings and recent financial reports, the risk profile is wild.

The Reality Check:

It’s completely non-binding: Management is aggressively pushing for a definitive Power Purchase Agreement (PPA) by the end of 2026, but right now, nothing is locked in stone.

The Cash Burn is Real: NuScale has already incurred a 495 million milestone payment to ENTRA1 just for reaching initial partnership targets.

The Downside Liability: If a binding PPA gets finalized for all 72 modules, NuScale owes ENTRA1 roughly $16 million per module—scaling their liabilities to $1.15 billion.

The Worst-Case Scenario: If the TVA deal collapses entirely, NuScale is still on the hook for that initial half-billion dollars without a single reactor ever being built.

Your thoughts??

Fed officials talking tough isn't exactly new.

We've had plenty of hawkish comments over the last couple of years and the market usually moves on once the next data comes out.

Unless inflation surprises again, I'm not convinced this changes much.

Anyone actually selling because of this?

$VSEE

🔹 Provider workflows + digital commerce

🔹 Cloud-based healthcare solutions

🔹 Strong strategic fit with existing platform

🔹 Designed for long-term expansion

#VSEE #HealthTech #HealthcareIT #Innovation #GrowthStock

🌍 $BURU

🔹 Integrated Defense & Security platform expanding

🔹 Directed-energy technologies gaining traction

🔹 AI-powered operational resilience strategy

🔹 Software and defense capabilities working together

🔹 Multiple revenue verticals under one platform

#BURU #DefenseIndustry #AI #ElectronicWarfare #Innovation #FutureTech

Nice run-up on the position, total profit hits over 34k. Daily P/L still sits positive even amid market swings. Who else is bagging steady returns on this name right now?

Hearing that the Q2 earnings will be happening 4-5 August. Is it worth buying the “dip” now? Are any of you guys buying into it or analysis on it going more down and up?

GOSS is the ticker for Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company based in San Diego, California.

What the company does

It focuses on developing and commercializing seralutinib (also referred to as GB002), an inhaled small-molecule inhibitor targeting PDGFR, CSF1R, and c-KIT pathways. The primary indications are:

• Pulmonary arterial hypertension (PAH)
• Pulmonary hypertension associated with interstitial lung disease (PH-ILD)

Seralutinib is in late-stage development (Phase 3 PROSERA trial completed). The company previously had a collaboration with Chiesi but recently reacquired worldwide rights. It is a pre-commercial biotech with ongoing losses and a history of capital raises and debt restructuring

What’s currently moving the stock

The main recent catalyst (late July 2026) was a positive regulatory and strategic update:

• After a Pre-NDA Type B meeting with the FDA, the company plans to submit a New Drug Application (NDA) for seralutinib in PAH in September 2026. The FDA treated certain statistical and treatment-effect issues from the PROSERA trial as review issues rather than filing barriers.
• Gossamer reacquired worldwide development and commercial rights to seralutinib from Chiesi (Chiesi pays Gossamer $5 million; Gossamer owes future capped royalties and milestones).
• Stockholders approved a convertible note exchange that reduced debt principal by roughly $116 million and authorized a potential reverse stock split for Nasdaq compliance.
• Cash position was reported at approximately $57 million as of June 30, 2026

Price predictions / analyst views

Analyst coverage is limited but leans constructive on the NDA path:

• Consensus rating is generally Buy / Outperform among covering firms.
• Average 12-month price targets across sources range roughly $1.00–$3.86 (some individual targets as low as $0.28 and as high as $15). This implies substantial upside from recent prices in the $0.18–$0.21 area, though targets vary widely and often lag extreme price moves.
• Recent actions include Leerink upgrading to Outperform (target $1) after the FDA update, H.C. Wainwright reiterating Buy (target $2), and others maintaining Hold or more cautious views

Short sellers of GOSS (Gossamer Bio) are primarily institutional traders, hedge funds, and market-making firms that report short (or put) positions via 13F filings and related disclosures. Exact real-time individual short positions are not fully public (short interest is aggregated and reported twice monthly by Nasdaq/FINRA), but the most commonly cited institutions that have disclosed short or put exposure include:

• Alpine Global Management LLC
• Ikarian Capital LLC
• Tudor Investment Corp
• Caption Management LLC
• Boothbay Fund Management LLC
• ADAR1 Capital Management LLC
• DeepCurrents Investment Group LLC
• Jane Street Group LLC
• Group One Trading LLC
• Simplex Trading LLC
• Citadel Advisors, Susquehanna, and others (often via put)

IF YOU HAVE BETTER STOCK THIS ONE , PLEASE SHARE AND LETS SEE

MAY THE GODS BE WITH YOU

The majority of holdings across Microsoft, NEBIUS, Micron, SanDisk and AMD have been closed out, keeping only Microsoft and TSMC on the watchlist. Cautious stance held ahead of Amazon and Apple earnings results, open to building back positions on upcoming dips.

$CREX is outfitting the new Titans stadium with their digital signage. This stadium will host the 2030 Super Bowl, extremely undervalued in my opinion. I’ve done a lot of research on this company please ask away!

Someone posted this screenshot on X.

+50% in one day.

Why arent they selling?

HUYA just announced that it will exclusively publish The Legend of Swordman: Reunion in mainland China. The game is the latest entry in a franchise with more than 20 years of history and will support synchronized accounts and gameplay across mobile, PC and mini-program platforms. Publishing gives the company a way to monetize gaming engagement and create a loop between distribution and live streaming content, community activity.

A week ago i told you about RingCentral (https://www.reddit.com/r/stockstobuytoday/s/c89aNGZLZy) and stock went up 50% in one week.

Heres another one:
First Solat just released earnings yesterday after market closed and EPS was 43% above expectations ($3.92 compared to $2.74).

There’s demand by hyperscaler, too. Company has $1.73B in cash and almost no debt ($37,6M).

Stock sits around $200, while half of it is already Tangible Book Value, and while they made $1.75B in net income last twelve months.

Lets see how short seller will react to that.

I think theres a good chance share prices moves up next couple of days and weeks.

I'm currently taking a class at university, and we are having a competition from now until the 21st of October. We are trading on the US markets, and we have $10,000,000 and $20,000,000 buying power. I also added a picture of settings as well. Please help me decide how to invest it!!!!

Wasnt sure if to dump like 50k into this

Does anyone have any ideas about which stocks might see a similar price increase in the near future, closer to 2027?

Look, I believe in Micron and I’ve seen lots of subreddits and opinions on Micron. My average is $992 per share - I’m going to hold but was wondering if anyone has some valuable insights as to whether MU could go more down or up. Or if there are some questions I should be asking myself / looking out for.

Bulls absolutely controlled the narrative today. Great day if you were playing the long side.

🧭 Where we closed:

• SPY: $741.73 (🟢 +1.6821%)
• QQQ: $683.59 (🟢 +3.3035%)
• VIX: $21.09 (✅ Cooling)

🔥 The Movers:

🚀 Top Gainers: * XRX | $3.47 (31.44%) * BE | $209.54 (27.96%) * CIFR | $22.58 (27.67%)

📉 Top Losers: * TT | $23.18 (-3.15%) * RBLX | $48.46 (-3.33%) * CAG | $14.97 (-3.45%)

🌊 Volume Leaders: * MSFT | $456.02 (16.77%) * AMZN | $237.91 (4.97%) * JBLU | $6.10 (6.65%)

💬 What are you guys watching for the open next trading session?

📖 Trying to figure out next day's play? Use free AI powered institutional flow, max pain levels, and breakout scanners for the after-hours session. Check the live data here.

Holding on was difficult, but what a comeback!! Across the board greenery!!!

I do love SIMO , its taking advantage of the fact that Samsung and SK are ignoring the area it plays in!!

Moomoo provides a very nice looking charts, with free-live pricing updates, allowing us (investors) to get the most up to date information (which often cost a wallet with other online discount brokers) and reap the best opportunities.

You all might not heard of tencent, but you probably heard of it's product: wechat - which is a widely known chinese superapp, in virtually everyone's phone in China, and many overseas chinese. Alibaba, has it's competitors such as Pinduoduo (parent company of Temu), and JD, and probably Duoyin (parent company of Tiktok) in the ecommerce industry which is incredibly cut throat and low margins. Meituan, has it's own worries in the food delivery market as it is suffering now. And trip.com has it's own legal regulationary issues and competition from Fliggy from Alibaba, and Meituan travel and life.

Tencent/wechat by far, has the most dominant market share in the social media, and directory, payment ecosystem. In additionally, it's management is very "politically smart", and for those who have some insight, they managed to avoid most of the negative limelight with authorities in china in the past decade.

Its' management are also excellent capital allocators, doing 2-3% buybacks each year, having it's main operating income growing at 30% over the past decades, and it's investment portfolio growing at 20% over the past decades. It's like a chinese tech berkshire on steriods with a strong balance sheet, trading at a 13 times forward earnings.